专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009117482A1 MTOR INHIBITOR SALT FORMS 审中-公开
标题翻译： MTOR抑制剂盐形式
公开(公告)号：WO2009117482A1
公开(公告)日：2009-09-24
申请号：PCT/US2009037505
申请日：2009-03-18
申请人： OSI PHARM INC , CASTELHANO ARLINDO L , MULVIHILL KRISTEN MICHELLE , BEIERSDORF AG , RECHKA JOSEF A
发明人： CASTELHANO ARLINDO L , MULVIHILL KRISTEN MICHELLE , BEIERSDORF AG , RECHKA JOSEF A
IPC分类号： C07D487/04 , A61K45/06
CPC分类号： C07D487/04
摘要： Salt forms of mTOR inhibitors of the Formula (I) and methods of preparation, formulation, and use in treating disease.
摘要翻译：式（I）的mTOR抑制剂的盐形式以及制备，制备和用于治疗疾病的方法。

2. 发明申请

WO2005021544A2 N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS 审中-公开
标题翻译： N3取代的咪唑吡啶C-CIT抑制剂
公开(公告)号：WO2005021544A2
公开(公告)日：2005-03-10
申请号：PCT/US2004026483
申请日：2004-08-16
申请人： OSI PHARM INC , CASTELHANO ARLINDO L , CREW ANDREW PHILLIP , DONG HAN-QING , LAUFER RADOSLAW , LI AN-HU , QUI LI , SAMBROOK SMITH COLIN PETER , ZHANG TAO
发明人： CASTELHANO ARLINDO L , CREW ANDREW PHILLIP , DONG HAN-QING , LAUFER RADOSLAW , LI AN-HU , QUI LI , SAMBROOK SMITH COLIN PETER , ZHANG TAO
IPC分类号： A61K31/435 , C07D471/04 , C07D471/00
CPC分类号： C07D471/04
摘要： Compounds represented by Formula (I): (I) or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
摘要翻译：由式（I）表示的化合物：（I）或其药学上可接受的盐或N-氧化物可用于治疗癌症。

3. 发明申请

WO2005021531A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS 审中-公开
标题翻译： N-取代苯并咪唑C-CIT抑制剂
公开(公告)号：WO2005021531A1
公开(公告)日：2005-03-10
申请号：PCT/US2004/026482
申请日：2004-08-16
申请人： OSI PHARMACEUTICALS, INC. , BOLGER, Joshua , CASTELHANO, Arlindo, L. , CREW, Andrew, Philip , DONG, Han-Qing , HONDA, Ayako , LAUFER, Radoslaw , LI, An-Hu , MULVIHILL, Kristen , QUI, Li , SAMBROOK, SMITH, Colin, Peter , SUN, Yingchuan , WYNNE, Graham, Michael , ZHANG, Tao
发明人： BOLGER, Joshua , CASTELHANO, Arlindo, L. , CREW, Andrew, Philip , DONG, Han-Qing , HONDA, Ayako , LAUFER, Radoslaw , LI, An-Hu , MULVIHILL, Kristen , QUI, Li , SAMBROOK, SMITH, Colin, Peter , SUN, Yingchuan , WYNNE, Graham, Michael , ZHANG, Tao
IPC分类号： C07D401/12
CPC分类号： C07D235/06 , C04B35/632 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D417/14
摘要： Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
摘要翻译：由式（I）表示的化合物或其药学上可接受的盐或N-氧化物可用于治疗癌症。

4. 发明申请

WO2003048120A2 COMPOUNDS SPECIFIC TO ADENOSINE A1 AND A3 RECEPTORS AND USES THEREOF 审中-公开
标题翻译：腺苷A1和A3受体特异性化合物及其用途
公开(公告)号：WO2003048120A2
公开(公告)日：2003-06-12
申请号：PCT/US2002/038055
申请日：2002-11-27
申请人： OSI PHARMACEUTICALS, INC. , CASTELHANO, Arlindo, L. , McKIBBEN, Bryan , WERNER, Douglas, S. , WITTER, David
发明人： CASTELHANO, Arlindo, L. , McKIBBEN, Bryan , WERNER, Douglas, S. , WITTER, David
IPC分类号： C07D
CPC分类号： C07D487/04
摘要： This invention pertains to compounds which specifically inhibit the adenosine A 1 and A 3 receptors and the use of these compounds to treat a disease associated with A 3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.
摘要翻译：本发明涉及特异性抑制腺苷A1和A3受体的化合物以及这些化合物用于治疗受试者中与A3腺苷受体相关的疾病的用途，其包括向受试者施用治疗有效量的化合物。

5. 发明申请

WO2012016095A1 PROCESS FOR THE PREPARATION OF THE COMPOUND OSI - 906 审中-公开
标题翻译：化合物OSI的制备方法 - 906
公开(公告)号：WO2012016095A1
公开(公告)日：2012-02-02
申请号：PCT/US2011/045807
申请日：2011-07-29
申请人： OSI PHARMACEUTICALS, LLC , CASTELHANO, Arlindo, L. , CUTTING, Gary, A. , LOCKE, Andrew, J. , MAO, Yunyu , MULVIHILL, Kristen, Michelle , NORRIE, Robert , O'BRIEN, Andrew, J. , PARK, Stuart, R. , RECHKA, Josef, A. , STEVENS, Andrew, Michael , THOMAS, Christopher, I.
发明人： CASTELHANO, Arlindo, L. , CUTTING, Gary, A. , LOCKE, Andrew, J. , MAO, Yunyu , MULVIHILL, Kristen, Michelle , NORRIE, Robert , O'BRIEN, Andrew, J. , PARK, Stuart, R. , RECHKA, Josef, A. , STEVENS, Andrew, Michael , THOMAS, Christopher, I.
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： Process for preparing the tyrosine kinase inhibitor OSI-906 comprises coupling Compound (2) with Compound (6) under specified conditions.
摘要翻译：制备酪氨酸激酶抑制剂OSI-906的方法包括在特定条件下将化合物（2）与化合物（6）偶联。

6. 发明申请

WO2011163430A1 POLYMORPHS OF OSI-906 审中-公开
标题翻译： OSI-906的多重性
公开(公告)号：WO2011163430A1
公开(公告)日：2011-12-29
申请号：PCT/US2011041547
申请日：2011-06-23
申请人： OSI PHARMACEUTICALS LLC , CASTELHANO ARLINDO L , ENGERS DAVID A , HANKO JASON A , RECHKA JOSEF A , TENG JING , YANG YONGLAI
发明人： CASTELHANO ARLINDO L , ENGERS DAVID A , HANKO JASON A , RECHKA JOSEF A , TENG JING , YANG YONGLAI
IPC分类号： C07D487/04 , A61K31/4985 , A61P35/00
CPC分类号： C07D487/04 , A61K31/4985
摘要： Polymorphic forms of the tyrosine kinase inhibitor OSI-906, preparation, pharmaceutical compositions, and uses thereof. The invention includes methods of treating diseases such as cancer, including cancer mediated at least in part by IGF-1 R and/or IR, with the polymorphs and compositions. This Abstract is not limiting of the invention.
摘要翻译：酪氨酸激酶抑制剂OSI-906的多形态，制剂，药物组合物及其用途。本发明包括治疗诸如癌症的疾病的方法，包括至少部分地通过IGF-1R和/或IR介导的癌症与多晶型物和组合物。本发明并不限于本发明。

7. 发明申请

WO2007067709A1 PROCESS TO PREPARE SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS 审中-公开
标题翻译：制备取代的咪唑并吡嗪化合物的方法
公开(公告)号：WO2007067709A1
公开(公告)日：2007-06-14
申请号：PCT/US2006/046764
申请日：2006-12-07
申请人： OSI PHARMACEUTICALS, INC. , MULVIHILL, Kristen, Michelle , CASTELHANO, Arlindo, L.
发明人： MULVIHILL, Kristen, Michelle , CASTELHANO, Arlindo, L.
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： A method of preparing formula (A) ,wherein, X=C1, Br, I, comprises the step of treating formula (B), with N-chloro-, N-bromo-, or N-iodosuccinimide in a compatible solvent such as dimethylformamide (DMF) at 0-60° C followed by halogenation.
摘要翻译：制备式（A）的方法，其中X = Cl，Br，I包括用相容溶剂中的N-氯 - ，N-溴 - 或N-碘代琥珀酰亚胺处理式（B）的步骤，例如二甲基甲酰胺（DMF），0-60℃，随后卤化。

8. 发明申请

WO2003053361A2 PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE 审中-公开
标题翻译：吡咯烷酮A2b选择性拮抗剂化合物，它们的合成和用途
公开(公告)号：WO2003053361A2
公开(公告)日：2003-07-03
申请号：PCT/US2002/040890
申请日：2002-12-20
申请人： OSI PHARMACEUTICALS, INC. , CASTELHANO, Arlindo, L. , McKIBBEN, Bryan , STEINIG, Arno, G.
发明人： CASTELHANO, Arlindo, L. , McKIBBEN, Bryan , STEINIG, Arno, G.
IPC分类号： A61K
CPC分类号： C07D487/04
摘要： The subject invention provides compounds having the structure: wherein, R 1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, -C(=O)NR a R b , -NR a R b , -NRaC(=O)NR a R b , -NR a C(=O)OR a , -OC(=O)NR a R b , or -NHC(=O)R a ; R 2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxyl, carboxyl, -C(=O)NR a R b , -NR a R b , -NR a C(=O)NR a R b , -NR a C(=O)OR a , -OC(=O)NR a R b , or -NHC(=O)R a , or R 1 , R 2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with -(CH 2 ) 2 OH or -CH 2 C(=O)OH; R 3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C 1 -C 15 )alkyl, (C 1 -C 15 )alkoxyl, or -NR a R b ; R 4 is hydrogen or substituted or unsubstituted (C 1 -C 15 )alkyl; R 5 is -(CH 2 ) m OR 6 , -CHNOR 7 , -C(=O)NR 8 R 9 , -(CH 2 ) m C(=O)OR 10 , -(CH 2 ) k C(=O)NR 11 R 12 ; wherein R 6 is a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring; R 7 is hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl; R 8 and R 9 are each independently hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl, (C 1 -C 30 )alkylamino, (C 1 -C 30 )alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, or R 8 , N, and R 9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring; R 10 is hydrogen or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or heterocyclic ring; R 11 , N and R 12 together form a 4-8 membered heterocyclic ring; R a and R b are each independently hydrogen or alkyl; m is 0, 1, 2 or 3; and k is 1, 2 or 3, or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A 2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.
摘要翻译：具有以下结构的化合物，其中R 1是取代或未取代的烷基，其中所述取代基是羟基，二羟基，羧基，-C（= O）NR b R a， sb> b ，-NR a R sb> b ，-NR a C（= O）NR a s b> （= O）OR a sb>，-OC（= O）NR a s b> a a sb>或-NHC（= O）R sb> a ; R 2是氢或取代或未取代的烷基，其中所述取代基是羟基，二羟基，羧基，-C（= O）NR b R a R b， sb>，-NR a b a a R b s b C b C b C a C b C b C b C b C a C b R b s > b ，-NR a C（= O）OR a ，-OC（= O）NR a 或者-NHC（= O）R a a a / bb，或R 1，R 2和R 3共同形成取代基哌嗪，取代的氮杂环丁烷环，或被 - （CH 2）2 - （OH）或-CH 2 S 2 C（= O）OH取代的吡咯烷环 ; R 3是取代或未取代的苯基或5-6元杂芳基环，其中取代基是卤素，羟基，氰基，（C 1 -C 15）-C 15 烷基，（C 1 -C 15烷基）烷氧基，或-NR b R b，b b b， ; R 4是氢或取代或未取代的（C 1 -C 15）烷基; R 5是-S（CH 3）2，其中R 1是-S（CH 3）s，，-C（= O）NR 8 R 9， - （CH 2）s（= O））OR 10 ， - （CH 2 ） k C（= O）NR 11 < 。

9. 发明申请

WO2011163430A9 POLYMORPHS OF OSI-906 审中-公开
公开(公告)号：WO2011163430A9
公开(公告)日：2011-12-29
申请号：PCT/US2011/041547
申请日：2011-06-23
申请人： OSI PHARMACEUTICALS, LLC , CASTELHANO, Arlindo, L. , ENGERS, David, A. , HANKO, Jason, A. , RECHKA, Josef, A. , TENG, Jing , YANG, Yonglai
发明人： CASTELHANO, Arlindo, L. , ENGERS, David, A. , HANKO, Jason, A. , RECHKA, Josef, A. , TENG, Jing , YANG, Yonglai
IPC分类号： C07D487/04 , A61P35/00 , A61K31/4985
摘要： Polymorphic forms of the tyrosine kinase inhibitor OSI-906, preparation, pharmaceutical compositions, and uses thereof. The invention includes methods of treating diseases such as cancer, including cancer mediated at least in part by IGF-1 R and/or IR, with the polymorphs and compositions. This Abstract is not limiting of the invention.

10. 发明申请

WO2005021537A1 N-SUBSTITUTED PYRAZOLYL-AMIDYL-BENZIMIDAZOLYL C-KIT INHIBITORS 审中-公开
标题翻译： N-取代的吡唑并咪唑基苯并咪唑C-CIT抑制剂
公开(公告)号：WO2005021537A1
公开(公告)日：2005-03-10
申请号：PCT/US2004/026481
申请日：2004-08-16
申请人： OSI PHARMACEUTICALS, INC. , BOLGER, Joshua , CASTELHANO, Arlindo, L. , CREW, Andrew, Phillip , LAUFER, Radoslaw , LI, An-Hu , SAMBROOK, SMITH, Colin, Peter , SUN, Yingchuan
发明人： BOLGER, Joshua , CASTELHANO, Arlindo, L. , CREW, Andrew, Phillip , LAUFER, Radoslaw , LI, An-Hu , SAMBROOK, SMITH, Colin, Peter , SUN, Yingchuan
IPC分类号： C07D403/12
CPC分类号： C07D403/12
摘要： Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
摘要翻译：由式（I）表示的化合物或其药学上可接受的盐或N-氧化物可用于治疗癌症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式